(SeaPRwire) –

By: Ethan Gallagher

Most mid-sized European clinical genomics labs waste 25 to 35 percent of staff hours on manual workflow validation. I spoke to four lab operations leads at ESHG this week, all frustrated with how long it takes to get new NGS tests cleared for clinical use. MGI’s announcements here aren’t just generic partnership fluff, they’re targeting a pain point competitors have ignored for years.

The official release frames the new NGS Partner Enablement Program as a way to connect assay developers, software providers and clinical labs to build validated workflows on MGI platforms, and cut time to market for regulated NGS applications. What they don’t say out loud? This is a direct play to poach customers from competing sequencing vendors. Most labs stick with familiar platforms to avoid 6+ months of costly, uncompensated validation work for new tests. MGI is eliminating that switching cost entirely.

The official announcement also notes new OEM partnership opportunities for MGI’s DE Bundles, including the upcoming D16 library prep system paired with the E25’s new 50M flow cell. The D16 launches later this year, with double the throughput of the existing D4 model and full enclosed contamination control. The unstated goal here is to expand reach without building out their own niche sales teams. Third-party solution providers can white label this hardware, and bring MGI’s tech to small specialized labs they would never target directly. They also showcased the T7+ ultra-high-throughput sequencer, with 27 units installed globally as of the end of 2025.

By the end of 2027, MGI will hold 23 percent of the European clinical sequencing hardware market, up from 9 percent at the close of 2025.

Author bio: Ethan Gallagher, Silicon Valley hardware architect and infrastructure strategist focused on life sciences tooling commercialization and supply chain mapping.